Precision medicines in development for neurodegenerative diseases, starting with CLN1 Batten Disease.
Circumvent Pharmaceuticals is developing precision medicines for neurodegenerative diseases by studying the palmitoylome and its role in synaptic function. Their lead program targets CLN1 Batten Disease, a fatal childhood neurodegeneration caused by CLN1 gene mutations affecting palmitoylation. The company uses high-fidelity animal models and has developed insights into palmitoylome architecture that may broadly apply to rare and common neurodegenerative disorders. No approved treatments are currently available for CLN1 Batten Disease. Circumvent Pharmaceuticals is a product of Circumvent.